Stay updated with breaking news from Darragh Lyons. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Malin Corporation said that its investee company Immunocore has announced the pricing of its initial public offering (IPO) at a price of $26 per share which will result in total gross proceeds of about $258m.
State-backed life sciences investment firm Malin is in a position to realise significant value from yet another of its shareholdings after Immunocore filed for an initial public offering (IPO). Immunocore, a cancer treatment biotech and one of Malin's key holdings, filed on Friday with the US Securities and Exchange Commission (SEC) to raise up to $100m (€83m) by listing on the Nasdaq. Malin has a 7pc stake in Immunocore, one of the company's four priority assets, valued at €49.8m as of August 2020. The development means Malin shareholders, including the State, could be in line for a bigg...
MALIN, the life sciences investment company backed by the State, has begun the process of raising money for pay-outs to investors in the second half of 2021, in line with a plan announced last month.
Malin Corporation said its investee immunotherapy company Kymab has been bought by French drugmaker Sanofi in a deal worth up to $1.45 billion.
Malin to make up to $145m from sale of Kymab to Sanofi Irish life sciences company holds 10% stake in immunotherapy firm Mon, Jan 11, 2021, 09:53 Irish life sciences investment group Malin is set to net up to about $145 million (€120 million) from the sale of British immunotherapy firm Kymab to French drug maker Sanofi. The deal, which will see Sanofi pay $1.1 billion up front, will give it full rights to Kymab’s KY1005, an antibody therapy viewed as having the potential to treat a wide range of inflammatory disorders and immune-related diseases. KY1005 passed a mid-stage Phase IIa cl...